Abstract: Provided are methods and compositions comprising antibodies capable of specific binding to human CEACAM1 molecules, for treating and diagnosing cancer as well as assessing CEACAM1 expression in tumor infiltrating immune cells (TILs) in a biological sample obtained from a [cancer] subject.

Abstract: Antibodies or antigen binding fragments thereof that bind HVEM, inhibit HVEM-BTLA interaction and allow binding to LIGHT are provided. Methods of treating disease with these antibodies or antigen binding fragments thereof, nucleic acid molecules encoding these antibodies or antigen binding fragments thereof and kits comprising these antibodies or antigen binding fragments thereof are also provided.

Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Abstract: The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function.

Abstract: Methods of determining suitability of a subject to be treated with a PD-1/PD-L1 based immunotherapy, comprising receiving a sample from the subject and determining HVEM levels in the sample, wherein expression of HVEM above a predetermined threshold indicates the subject is suitable to be treated by the immunotherapy or of determining suitability of a subject non-responsive to a PD-1/PD-L1 based immunotherapy to be treated by an HVEM based immunotherapy, comprising receiving a sample from the subject and determining T cell levels in the sample, wherein T cell levels above a predetermined threshold indicates the subject is suitable to be treated by the HVEM based immunotherapy are provided.

Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.

Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.

Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Abstract: Agents that bind HVEM, inhibit HVEM-BTLA interaction and activate downstream HVEM signaling are provided. Methods of treating disease with those agents and kits comprising those agents are also provided.

Abstract: A general-purpose mobile communication device, general-purpose computer user-interface device, and other non-health-related electronic devices with cardiovascular monitoring capability. Various aspects of the present invention may comprise a general-purpose mobile communication device (e.g., a cellular telephone, portable email device, personal digital assistant, etc.) comprising a communication interface module adapted to communicate with a general-purpose communication network, and at least one module operational to acquire cardiac information from a user of the general-purpose mobile communication device. The general-purpose communication device may, for example, comprise a cardiac sensor (e.g., electrodes) disposed on the mobile communication device, which may be utilized to acquire cardiac information during use of the mobile communication device. Various aspects of the present invention may also comprise a non-health related electronic device (e.g.

Abstract: A general-purpose mobile communication device, general-purpose computer user-interface device, and other non-health-related electronic devices with cardiovascular monitoring capability. Various aspects of the present invention may comprise a general-purpose mobile communication device (e.g., a cellular telephone, portable email device, personal digital assistant, etc.) comprising a communication interface module adapted to communicate with a general-purpose communication network, and at least one module operational to acquire cardiac information from a user of the general-purpose mobile communication device. The general-purpose communication device may, for example, comprise a cardiac sensor (e.g., electrodes) disposed on the mobile communication device, which may be utilized to acquire cardiac information during use of the mobile communication device. Various aspects of the present invention may also comprise a non-health related electronic device (e.g.

Abstract: The invention relates to methods and compositions for the treatment and diagnosis of cancers. At least one aspect of the present invention relates to methods and compositions for enhancing the efficacy of tumor-infiltrating lymphocyte (TIL) therapy in the treatment of cancer by negatively modulating the activity of the CEACAM1 protein.

Abstract: The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the suppression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue.

Abstract: A garment and/or garment system with health-monitoring (e.g., cardiovascular monitoring) capability, substantially as shown in and/or described in connection with at least one of the figures, as set forth more completely in the claims.

Abstract: A garment and/or garment system with health-monitoring (e.g., cardiovascular monitoring) capability, substantially as shown in and/or described in connection with at least one of the figures, as set forth more completely in the claims.

Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.

Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.

Abstract: The present technology regards the utilization of CAECAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CAECAM1 levels for the detection and diagnosis of melanoma.

Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.